Cite
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.
MLA
Hashmi, Hamza, et al. “Haemophagocytic Lymphohistiocytosis Has Variable Time to Onset Following CD19 Chimeric Antigen Receptor T Cell Therapy.” British Journal of Haematology, vol. 187, no. 2, Oct. 2019, pp. e35–38. EBSCOhost, https://doi.org/10.1111/bjh.16155.
APA
Hashmi, H., Bachmeier, C., Chavez, J. C., Song, J., Hussaini, M., Krivenko, G., Nishihori, T., Kotani, H., Davila, M. L., Locke, F. L., & Jain, M. D. (2019). Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. British Journal of Haematology, 187(2), e35–e38. https://doi.org/10.1111/bjh.16155
Chicago
Hashmi, Hamza, Christina Bachmeier, Julio C. Chavez, Jinming Song, Mohammad Hussaini, Gabriel Krivenko, Taiga Nishihori, et al. 2019. “Haemophagocytic Lymphohistiocytosis Has Variable Time to Onset Following CD19 Chimeric Antigen Receptor T Cell Therapy.” British Journal of Haematology 187 (2): e35–38. doi:10.1111/bjh.16155.